A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Must have received: bevacizumab-containing therapy (bevacizumab) — at least 1 line

At least 1 line of therapy containing bevacizumab, unless the subject is not eligible for treatment with bevacizumab due to precautions/intolerance.

Must have received: systemic anticancer therapy — at least 1 but no more than 3 prior systemic lines of anticancer therapy

Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy. Subjects must have progressed radiologically on or after their most recent line of systemic therapy.

Must have received: platinum-based chemotherapy — platinum-resistant disease

Has platinum-resistant disease. If a subject had only 1 line of platinum therapy, must have received at least 4 cycles of platinum, must have had a best response of not PD, and then progressed between >90 and ≤180 days after the date of the last dose of platinum. If a subject had 2 or 4 lines of platinum therapy, must have received at least 2 cycles of platinum and have progressed on or within 180 days after the date of the last dose of platinum.

Must have received: mirvetuximab soravtansine (mirvetuximab soravtansine) — if locally available and high-folate receptor alpha expression

Has had prior treatment with MIRV for participants with documented high-folate receptor alpha expression, unless the participant is not eligible for treatment with mirvetuximab soravtansine due to precautions/intolerance, or if the treatment is not approved or available locally.

Cannot have received: CDH6-targeted agent

Prior exposure to other CDH6-targeted agents

Cannot have received: antibody-drug conjugate containing a topoisomerase I inhibitor (trastuzumab deruxtecan, datopotamab deruxtecan)

Prior exposure to an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan or datopotamab deruxtecan). For Phase 3 (Part B): Prior exposure to other CDH6-targeted agents or an antibody-drug conjugate containing a topoisomerase I inhibitor.